Dynatrace Seeing Healthy Demand, but Acceleration Becoming Show-Me Story, Morgan Stanley Says

MT Newswires Live05-14

Dynatrace (DT) is facing a healthy demand scenario but the company's shares may mark time in the near-term as revenue acceleration is becoming a show-me story, Morgan Stanley said in a note emailed Thursday.

The investment firm said that with the company's Q4 results, annual recurring revenue growth was kept at 16% for the fourth quarter in a row, in line with guidance. However, the company's 2027 constant currency annual revenue guidance for 15.5% to 16.5% growth is now above consensus estimates, the note said.

Morgan Stanley said that investors may see the initial 2027 annual recurring revenue outlook as "aggressive" since the company's net-new annual recurring revenue increased just about 10% in H2.

The investment firm added, however, a solid demand background, considerable renewals, as well as improving sales productivity may back an acceleration in net new annual recurring revenue in 2027.

Morgan Stanley has an equal-weight rating on Dynatrace and lowered the company's price target to $40 from $43.

Price: 36.31, Change: +1.58, Percent Change: +4.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment